regulatory risk

Aquestive Therapeutics faces class action lawsuit alleging securities fraud over false FDA approval statements and concealed anaphylaxis product risks.

Class action lawsuit filed against $TCOM alleging securities fraud over false regulatory risk statements from April 2024 to January 2026.

Rosen Law Firm files securities class action against Trip.com Group Limited ($TCOM), urging investors with losses exceeding $100K to secure counsel before May 11, 2026 deadline.

Rosen Law Firm launches securities class action against Trip.com ($TCOM) over alleged false regulatory risk disclosures. Lead plaintiff deadline: May 11, 2026.

Robbins LLP filed class action against $TCOM for allegedly concealing antitrust risks. Stock dropped 19.4% after January 2026 antitrust probe disclosure.

Trip.com faces class action lawsuit alleging false regulatory risk disclosures regarding monopolistic practices. Lead plaintiff deadline set for May 11, 2026.

Meta and Super Micro Computer offer different AI exposure: Meta provides steady growth via advertising platform enhancement; SMCI presents volatile infrastructure play with regulatory and cyclical risks.

Rosen Law Firm initiates securities class action against $TCOM for allegedly understating regulatory risks from monopolistic practices. May 11 deadline for investors.

Trip.com faces class action lawsuit alleging false statements about regulatory risks tied to monopolistic practices during April 2024-January 2026 period.

Securities lawsuit filed against $TCOM for allegedly concealing antitrust investigation by Chinese regulators. May 11 deadline for lead plaintiff status.

Robinhood launches derivatives exchange Rothera with Susquehanna to tap prediction markets, seeking stable revenue beyond volatile cryptocurrency trading amid regulatory uncertainty.

Rosen Law Firm files securities class action against Trip.com Group ($TCOM), alleging false statements on business operations and regulatory risks. Investors urged to secure counsel before deadlines.

SpaceX's reported $1.75 trillion IPO valuation raises concerns about overpriced future promises, Elon Musk's divided focus, and regulatory uncertainties in space exploration.

Turning Point Brands stock drops 14% after FDA scientists express safety concerns about nicotine pouches, threatening approval of key products.

Grab stock rises 3.54% to $3.66 as investors embrace fuel surcharge strategy in Singapore set for April 7 rollout.

Kirby McInerney LLP filed class action lawsuit against $TCOM for allegedly understating monopoly investigation risks. Stock tumbled 17.1% after Chinese regulatory disclosure.

Capital One's 2026 will test its ability to integrate $35B Discover and $5.15B Brex acquisitions amid rising credit losses and a 25% stock decline.

Trip.com investors alleging false regulatory disclosures can pursue class action. Stock dropped 19% after China antitrust investigation revelation.

Class action lawsuit filed against $TCOM for alleged securities fraud involving undisclosed monopolistic business risks. Lead plaintiff deadline set for May 11, 2026.

Mark Cuban published a satirical IPO filing warning of regulatory and tax risks from AI automation, directly challenging Elon Musk's optimistic workforce predictions as SpaceX prepares to go public.